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Abstract
Pathway-based analysis has been recently used in joint tests of association between disease and a group of
common genetic variants. Here we explore this idea for the joint effects analysis of rare genetic variants and their
association with quantitative traits and disease. We accumulate multiple rare minor alleles in a genetic risk score for
each individual in a given pathway; this score is then used to assess association with quantitative phenotypes and
disease. We demonstrate that this approach may be better than studying single rare variants or a gene risk score
for identifying individuals with significantly greater risk.
Background
In the past few years, genome-wide association studies
have been widely used to identify genetic risk factors for
complex diseases. This analysis paradigm has made sig-
nificant progress in many genetic studies. For example,
so far, many variants have been discovered that are
associated with common diseases, such as type 2 dia-
betes [1]. To date, however, the utility of genetic mar-
kers to improve disease risk prediction still explains
only a small proportion of the genetic variance for many
complex diseases. This missing heritability might be
explained by common variants with weak effects and/or
additional rare variants with strong or weak effects, act-
ing additively and/or interacting with other genetic and
environmental variants [2]. For the common variants
explanation, multilocus-based genetic risk score and
pathway-based methods have been developed. For exam-
ple, the use of a multilocus genetic risk score has been
proposed to evaluate the risk of breast cancer and its
subtypes [3]. A pathway-based analysis strategy has been
used to search for related genes and common single-
nucleotide polymorphisms (SNPs) that contribute to
Parkinson’s disease [4]. For rare variants, methods for
statistical analysis are still limited. Here, we integrate
the multilocus genetic risk score and pathway analysis
strategies used for common variants to analyze rare
genetic factors and evaluate their association with
quantitative phenotypes and disease.
Methods
Data description
We use replicate 1 with 697 unrelated individuals from
the Genetic Analysis Workshop 17 (GAW17) data.
There are 24,487 autosomal SNPs. All SNPs and sam-
ples have a genotype call rate of 100%. We define rare
SNPs as those with a minor allele frequency (MAF) less
than 1%. For the phenotype data, there are three quanti-
tative risk factors (Q1, Q2, and Q4), which are simulated
as normally distributed phenotypes, and one disease risk
factor, for which there are 209 case subjects and 488
control subjects. Genes influencing Q1 and the disease
are primarily from the vascular endothelial growth fac-
tor (VEGF) pathway, whereas those influencing Q2 are
primarily associated with cardiovascular disease risk and
inflammation. There are no causal genes or pathways
related to Q4 [5].
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For each rare SNP, we performed linear regression ana-
lysis for association between genotypes and Q1, Q2, and
Q4 and logistic regression analysis for association
between genotypes and disease status. We adjusted for
sex, age, smoking, and population stratification by gen-
erating two dummy covariates for the three populations:
Asian, African, and European. Genotypes were coded
additively. We obtained the corresponding adjusted
odds ratio (OR) and P-value for each rare SNP.
Joint effects analysis of rare genetic variants
We analyzed the joint effects of rare genetic variants at
b o t ht h eg e n ea n dt h ep a t h w a yl e v e l .T h eo b j e c t i v ew a s
to test for association of an aggregation of rare minor
alleles with quantitative phenotypes and disease by
combing genetic information across multiple variants
within a given gene or pathway, respectively. To do this,
we first mapped rare SNPs to genes and pathways as
follows.
In step 1, we mapped rare SNPs to genes. We
obtained the nearest gene name for each rare SNP from
the snp_info file provided by GAW17. In step 2, we
mapped the genes from step 1 to the c2 curated canoni-
cal pathways (version 3) from the Broad Institute
(http://www.broadinstitute.org/gsea/msigdb/). This data-
base includes 888 gene sets collected from 186 pathways
from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (http://www.genome.jp/kegg/), 430 pathways
from Reactome, 217 pathways from BioCarta among
others. We kept only the pathways with at least five
genes in our data set, which left 472 pathways for fol-
low-up analysis. We note that each of these three data-
bases includes the VEGF causal pathway. In the next
step, we defined a genetic risk score for each individual
as the count of minor alleles of all rare variants in a
given gene or pathway [6]. Finally, we performed linear
and logistic regression analyses to test for the associa-
tion of the count of minor alleles with the traits (Q1,
Q2, Q4, and disease) in each gene and pathway, respec-
tively, by adjusting for sex, age, smoking, and population
stratification, similar to the univariate SNP association
analysis.
Results
We removed 1,314 SNPs that had a Hardy-Weinberg
equilibrium test P-value smaller than 1 × 10
−6 in con-
trol subjects, leaving 23,173 SNPs. We performed
multi-dimensional scaling analysis using these remaining
SNPs and identified seven outlier samples (Figure 1): One
outlier is European (red circles) and clusters with the
Asian group (green circles), and the other six outliers
are African (black circles) and are separate from the
major African cluster (lower right-hand corner). The
seven outlier samples include five control and two case
subjects. We removed these outliers in subsequent
analyses.
We focused on 18,094 rare variants (MAF < 1%) from
the 23,173 SNPs that passed quality control. Overall, we
did not find any rare variants with significant association
for Q2, Q4, and disease at the Bonferroni-corrected sig-
nificance level of 0.05 (corresponding to an unadjusted
P-value of 2.8 × 10
−6). We did find three rare variants
that were significantly associated with Q1 (Table 1).
One of these (C13S524) is in causal gene FLT1, whereas
the other two are not in any causal gene.
The 18,094 rare variants mapped to 2,439 genes. Of
these 2,439 genes, 911 had 1 rare SNP in each gene, 655
had 2–5 rare SNPs, and 873 had more than 5 rare
SNPs. The joint effects analysis of rare genetic variants
at the gene level did not identify significant association
for Q2, Q4, or disease at the Bonferroni-corrected sig-
nificance level of 0.05 (corresponding to an unadjusted
P-value of 2.1 × 10
−5). We found four genes that were
significantly associated with Q1 (Table 2), two of which
(FLT1 and KDR) were causal genes and two of which
(RGPD8 and EPHB1) were not causal genes.
The 2,439 genes that include at least one rare variant
were mapped to 472 canonical pathways. We did not
find significant association of pathways with either Q2
or Q4 at a Bonferroni-corrected significance level of
0.05 (corresponding to an unadjusted P-value of 1.0 ×
10
−4). The most significant pathway for Q2 was Reac-
tome Phase II Conjugation (P =6 . 5×1 0
−4), which did
not include causal genes.
As described before, each of the three pathway data-
bases (KEGG, Reactome, and BioCarta) includes the
VEGF causal pathway for Q1 and disease. We report the
association results of this causal pathway in Table 3,
which shows that the VEGF causal pathway in the three
databases is significantly associated with Q1 but is sig-
nificantly associated with disease only in the Reactome
and BioCarta databases. The likely reason for this is that
the VEGF pathway genes in KEGG include fewer causal
genes for either Q1 or disease than those in either Reac-
tome and BioCarta. All 5 genes of the VEGF pathway in
the Reactome database are causal genes for Q1; 9 of 11
genes of the VEGF pathway in the BioCarta database
are causal for either Q1 (6) or disease (3); and only 7 of
the 17 genes in the VEGF pathway in KEGG are causal
for either Q1 (2) or disease (5).
Because the VEGF pathway is significantly associated
with disease, as shown in Table 3, we present in Figure
2 the distributions of minor allele count in case and
control subjects for this pathway in the BioCarta and
Reactome databases. The figure clearly shows that the
rare minor allele count is significantly greater in case
subjects than in control subjects.
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pathways in different databases is driven by only one
rare SNP out of each gene in a given pathway, we did a
leave-one-out cross-validation (LOOCV). To do this
test, for each pathway we first removed one rare SNP
from each gene and then recalculated the genetic risk
score for each individual as the accumulation of minor
alleles for all rare variants in a given pathway by exclud-
ing the rare SNP. Finally, we performed the regression
analysis described earlier. We repeated these steps for
all the rare SNPs in a given pathway. Table 4 shows the
results for the VEGF causal pathways for Q1 and dis-
ease. The table clearly shows that the significance of the
VEGF causal pathway for Q1 is not affected by one sin-
g l er a r eS N Pb u tb ym u l t i p l er a r em i n o ra l l e l e si nt h e
pathway, whereas the disease risk is driven by a small
number of truly associated rare SNPs. For example, all
five SNPs in the BioCarta database and all six SNPs in
the Reactome database are in causal genes for either Q1
or disease.
Because our analysis has narrowed the associations to
the VEGF pathway in the three databases, we further
evaluated the associations between SNPs in the pathway
with Q1 and disease using a smaller Bonferroni correc-
tion based on the number of SNPs in the pathway in
each of the three databases (see P-value column in
Table 5). Based on the significance levels, we counted
the number of true positives (causal SNPs significantly
associated with Q1 or disease) and estimated the power
for Q1 and disease in the three databases. Our results
Table 1 Identified significant rare genetic variants for Q1
SNP Chromosome Position MAF P-value b (standard error) In causal gene?
C13S524 13 27,899,915 0.0043 2.33 × 10
−7 1.92 (0.37) Yes (FLT1)
C2S2355 2 112,864,155 0.0087 6.43 × 10
−7 1.31 (0.26) No (RGPD8)
C2S2174 2 107,855,174 0.0094 2.66 × 10
−6 1.04 (0.22) No (RGPD4)
Figure 1 Multidimensional scaling analysis of 697 samples from the 1000 Genomes Project. We used 23,173 SNPs in the multidimensional
scaling analysis and removed seven outlier samples (one European and six Africans) in the subsequent analysis. Red circles, Europeans; green
circles, Asians; black circles, Africans.
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Gene Chromosome Number of rare SNPs P-value b (standard error) Causal genes?
RGPD8 2 3 2.55 × 10
−8 1.30 (0.23) No
FLT1 13 25 7.37 × 10
−8 0.67 (0.12) Yes
KDR 4 14 8.52 × 10
−7 0.88 (0.18) Yes
EPHB1 3 6 1.53 × 10
−5 0.81 (0.19) No
Table 3 Association of rare SNPs in the VEGF pathway with traits in three databases
Trait Database Number of rare
SNPs
Number of genes in GAW17 data
set
Number of causal
genes
P-value Rank of
significance
Q1 Reactome 53 5 5 1.77 × 10
−15*
1
BioCarta 95 11 6 6.81 × 10
−14*
2
KEGG 66 17 2 1.83 × 10
−7*1 1
Disease Reactome 53 5 0 4.95 × 10
−5*3
BioCarta 95 11 3 4.69×10
−5*2
KEGG 66 17 5 2.17×10
−4 4
* Significant at corrected significance level of 0.05.
Figure 2 Distribution of minor allele counts in case and control subjects. The frequencies of minor alleles in different bins were estimated
for the VEGF pathway in the Reactome and BioCarta databases. Red bars, case subjects; blue bars, control subjects.
Table 4 LOOCV rare SNP results for VEGF pathway with trait in three databases
Trait Database Number of rare SNPs P-value (all SNPs) One SNP removed at a time
Number of times P ≤ 1×1 0
−4a Number of times P >1×1 0
−4
Q1 BioCarta 95 6.81 × 10
−14 95 0
Reactome 53 1.77 × 10
−15 53 0
KEGG 66 1.83 × 10
−7 66 0
Disease BioCarta 95 4.69 × 10
−5 90 5
Reactome 53 4.95 × 10
−5 47 6
KEGG 66 2.17 × 10
−4 16 5
a At corrected significance level 0.05.
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pathway and then detecting SNP associations in the cau-
sal pathway) has slightly larger power than trying to
detect SNP associations directly for Q1 (see Tables 2
and 5).
Discussion and conclusions
In this study, we evaluated the associations between rare
genetic variants and quantitative traits or disease status
at the SNP, gene, and pathway levels. Overall, we did
not find significant associations at the SNP, gene, and
pathway levels for Q2 and Q4, but we found that the
VEGF causal pathway is significantly associated with
both Q1 and disease status. We also found that one cau-
sal SNP and two causal genes are significantly associated
with Q1. We further confirmed that these enriched
pathway signals are not driven by a single rare SNP but
by multiple rare variants in multiple genes in the path-
ways for Q1. We assumed in our analysis that all minor
alleles influenced each trait with the same direction of
effect, because the minor allele in the simulated data is
associated with higher means of quantitative traits (Q1
and Q2) and liability (disease). However, this assump-
tion may not hold in real data, resulting in decreased
power to detect causal genes. We have also observed
that, although most of the causal genes for Q1 are not
the causal genes for disease, those causal genes for Q1
actually play a key role in disease (such as the five genes
of the VEGF pathway in the Reactome database). Our
results show that a simple but efficient pathway-based
analysis of rare genetic variants can identify potential
genetic risk factors that were missed in the SNP- and
gene-level analysis.
Our study does have some limitations. One is that our
analysis was focused on only one simulated data set. A
better strategy would be to analyze all simulated data
sets. Another limitation is that we assumed that there
was a linear relationship between the traits (Q1, Q2, and
Q4) and the covariates used in the study. We observed
that some of the covariates had a nonlinear relationship
with the traits. Therefore nonlinear regression models
may be more suitable. We will explore these models in
detail in the future.
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Table 5 Power of rare SNPs in the VEGF pathway
Trait Database Number of rare SNPs Number of causal rare SNPs P-value
a Power (%) (true positives)
Q1 BioCarta 95 33 9.34 × 10
−4 9.1 (3)
Reactome 53 25 5.26 × 10
−4 16.0 (4)
KEGG 66 11 7.58 × 10
−4 18.2 (2)
Disease BioCarta 95 5 9.34 × 10
−4 0 (0)
Reactome 53 0 5.26 × 10
−4 0 (0)
KEGG 66 7 7.58 × 10
−4 0 (0)
a Significant at corrected significance level 0.05.
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